Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Protagonist Therapeutics Inc PTGX

Healthcare Biotechnology

Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its... see more

Add To Watchlist

Recent & Breaking News (NDAQ:PTGX)

Protagonist Therapeutics Reports Granting of Inducement Award

PR Newswire May 3, 2021

Protagonist Therapeutics Completes Enrollment for Phase 2 Study of Rusfertide in Polycythemia Vera and Announces Plans for Data Update at an Upcoming Medical Meeting

PR Newswire April 27, 2021

Protagonist Announces Plans to Initiate a Global Phase 3 Study for Rusfertide in Polycythemia Vera Following Interactions with the U.S. Food & Drug Administration and the European Medicines Agency

PR Newswire March 22, 2021

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

PR Newswire March 10, 2021

Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results

PR Newswire March 3, 2021

Protagonist Therapeutics to Participate in the H.C. Wainwright Global Life Sciences Conference

PR Newswire March 2, 2021

Protagonist Therapeutics Reports Granting of Inducement Award

PR Newswire February 26, 2021

Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference

PR Newswire February 16, 2021

Protagonist Therapeutics Reports Granting of Inducement Award

PR Newswire January 29, 2021

Protagonist Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

PR Newswire January 4, 2021

Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)

PR Newswire December 16, 2020

Protagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

PR Newswire December 15, 2020

Protagonist Therapeutics, Inc. Announces Pricing of $100 Million Public Offering of Common Stock

PR Newswire December 10, 2020

Protagonist Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

PR Newswire December 10, 2020

Protagonist Announces Results of Large-Scale Analysis of Current Treatment Patterns Revealing Significant Opportunity to Improve the Standard of Care for Patients with Polycythemia Vera Across Broad Population Categories

PR Newswire December 7, 2020

Protagonist Announces Updated Phase 2 Data Presented at ASH Annual Meeting Supporting Long Term Efficacy of Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

PR Newswire December 6, 2020

Protagonist's Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designation from the U.S. Food and Drug Administration for Development in the Treatment of Polycythemia Vera

PR Newswire December 2, 2020

Protagonist Therapeutics Reports Granting of Inducement Award

PR Newswire December 1, 2020

Protagonist to Host Conference Call and Webcast to Provide a Research Update on December 9, 2020

PR Newswire November 30, 2020

Protagonist Therapeutics to Present at the Virtual Piper Sandler 32nd Annual Healthcare Conference

PR Newswire November 25, 2020